Last reviewed · How we verify
Intra-vitreal Anti-VEGF Drug — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intra-vitreal Anti-VEGF Drug (Intra-vitreal Anti-VEGF Drug) — Retina Vitreous Associates of Florida.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intra-vitreal Anti-VEGF Drug TARGET | Intra-vitreal Anti-VEGF Drug | Retina Vitreous Associates of Florida | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intra-vitreal Anti-VEGF Drug CI watch — RSS
- Intra-vitreal Anti-VEGF Drug CI watch — Atom
- Intra-vitreal Anti-VEGF Drug CI watch — JSON
- Intra-vitreal Anti-VEGF Drug alone — RSS
Cite this brief
Drug Landscape (2026). Intra-vitreal Anti-VEGF Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-vitreal-anti-vegf-drug. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab